Page last updated: 2024-08-25

lazabemide and Parkinson Disease, Secondary

lazabemide has been researched along with Parkinson Disease, Secondary in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M	1
Fukuda, T; Nomoto, M	1
LeWitt, PA; Mistura, KL; Schork, MA; Segel, SA	1

Trials

1 trial(s) available for lazabemide and Parkinson Disease, Secondary

Article	Year
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clinical neuropharmacology, 1993, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids; Selegiline	1993

Other Studies

2 other study(ies) available for lazabemide and Parkinson Disease, Secondary

Article	Year
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12 Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors	2011
A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology, 1993, Volume: 32, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids	1993

Article

Year

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors

2011

A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.

Neuropharmacology, 1993, Volume: 32, Issue:5

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids

1993